Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Ipatasertib||Phase I||Actionable||In a Phase I trial, Ipatasertib (GDC-0068) resulted in antitumor activity in 30% (16/52) of patients with advanced solid tumors, primarily demonstrating stable disease (PMID: 27872130).||27872130|
|Unknown unknown||Advanced Solid Tumor||not applicable||Ipatasertib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Ipatasertib (GDC-0068) demonstrated activity against tumor growth in cell line xenograft models of solid tumors (PMID: 24141624).||24141624|
|PubMed Id||Reference Title||Details|
|(24141624)||Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.||Full reference...|
|(27872130)||A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.||Full reference...|